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Background: Radiotherapy is widely used to treat cancer alone or in combination with surgery, chemotherapy, and
immunotherapy. However, damage to normal tissues and radioresistance of tumor cells are major obstacles to
successful radiotherapy. Furthermore, the immune network around tumors appears to be connected to tumor
progression and recurrence.
Methods: We investigated the cytosolic proteins produced by irradiated tumor cells by using a quantitative
proteomic approach based on stable isotope labeling by amino acids in cell culture. MDA-MB-231 breast cancer
cells were treated with a single or fractionated 10 Gray dose of 137Cs γ-radiation, which was selected based on cell
viability.
Results: Radiation-induced proteins were differentially expressed based on the fractionated times of radiation and
were involved in multiple biological functions, including energy metabolism and cytoskeleton organization. We
identified 46 proteins increased by at least 1.3-fold, and high ranks were determined for cathepsin D, gelsolin,
arginino-succinate synthase 1, peroxiredoxin 5, and C-type mannose receptor 2.
Conclusion: These results suggest that a number of tumor-derived factors upregulated by γ-radiation are promising
targets for modulation of the immune response during radiation treatment.
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Radiation therapy (RT) is one of the most common
treatments for cancer and can be provided alone or, fre-
quently, in combination with surgery, chemotherapy, or
immunotherapy [1,2]. Depending on the type of cancer,
50–90% of cancer patients undergo RT during the
course of their illness, with the highest percentages in
cases of non-small-cell lung cancer, prostate, breast, and
colon cancer [3,4]. However, RT is associated with acute
or chronic side effects such as injury to normal tissues,
fatigue, nausea/vomiting, diarrhea, and intestinal bleed-
ing. The effect of radiation on tumor cells varies greatly* Correspondence: immu@kirams.re.kr
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unless otherwise stated.according to the type of radiation, total dose, dose rate,
and time of testing post-exposure [4-7]. Therefore, the
reasons for RT failure are multiple and vary, and major
causes include inadequate vascular supply (hypoxia),
cancer stem cells, and novel mutations [8]. Furthermore,
tumors can survive in complex systems, including het-
erogeneous tumor cells, tumor-associated cells, normal
cells, and immune cells, rather than as a simple mass of
malignant cells. Notably, tumor-associated immune cells
produce various signals that are highly predictive of the
efficiency of RT as well as cancer progression and recur-
rence [9].
In the last several years, stimulation of the immune
system has been proposed to occur through immuno-
genic cell death (ICD) mediated mainly by danger signals
from endogenous damage-associated molecular patterns
(DAMPs) such as stress, damage or injury to tissues, andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tal roles of DAMPs in cancer therapy are highly contro-
versial [7,9]. Profiling the factors derived by irradiated
cancer cells could therefore provide new insights into
the prediction of radiation responsiveness.
Breast cancer is the most prevalent malignancy in
women and the second leading cause of cancer-related
deaths in developed countries. RT is widely used as part
of a tri-modal treatment with chemotherapy and surgery;
however, approximately 50% of breast cancer patients
have experienced malignant microfoci scattered through-
out the breast tissue that can easily progress to metastatic
breast cancer [10]. Therefore, new approaches are ur-
gently needed, and multimodal combinatorial therapy is
currently being investigated. To this end, we performed a
massive quantitative proteomic analysis of irradiated hu-
man breast cancer cells (MDA-MB-231) based on stable
isotope labeling by amino acids in cell culture (SILAC),
which has emerged as one of the most powerful tools for
accurate and robust quantitative proteomics, and liquid
chromatography–mass spectrometry (LC-MS) [11-13].
In this study, we demonstrated that the tumor-derived
proteins commonly increased by both single and fraction-
ated radiation are involved in multiple biological func-
tions. These results indicate promising ICD-associated
candidates for cancer treatment that may predict and
modify the response to RT.
Methods
Cell culture
The human breast cancer cell line MDA-MB-231 was
purchased from American Type Culture Collection
(ATCC, Manassas, VA, USA). The cells were maintained
at 37°C in RPMI 1640 with 10% fetal bovine serum (FBS;
Gibco BRL, Grand Island, NY, USA), 100 units/mL
penicillin, and 100 μg/mL streptomycin in a humidified
atmosphere with 5% CO2.
Cell viability tests
Cell viability was assessed by trypan blue and MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium brom-
ide) assays (Sigma-Aldrich, St. Louis, MO, USA) according
to the manufacturer’s recommendations. MDA-MB-231
cells were plated in 96-well plates (1 × 104 cells/well) in
triplicate for indicated times after irradiation. MTT (0.5
mg/mL) was added to each well for 3 h, and absorbance
was measured at 540 nm using a microplate reader
(Multiskan EX, Thermo LabSystems, Waltham, MA,
USA). Additionally, to ascertain cell death, cells were
incubated with 2.5 mg/mL propidium iodide (PI) for 5
min at room temperature and analyzed with a FACS-
Canto II flow cytometer (Becton Dickson, Franklin
Lakes, NJ, USA) and Flowing Software (version 2.5.1;
http://www.flowingsoftware.com/).Stable isotope labeling by amino acids in cell culture
MDA-MB-231 cells were maintained in L-lysine-de-
pleted RPMI 1640 (Invitrogen, Grand Island, NY, USA)
supplemented with 10% dialyzed FBS (Invitrogen, Carlsbad,
CA, USA) and 0.1 mg/mL heavy [U-13C6] or light L-lysine
(Invitrogen). Every 3–4 days, cells were split and media re-
placed with the corresponding light or heavy labeling
medium. After approximately six doubling times, cells
achieved almost 100% incorporation of amino acid iso-
topes. Cells grown with light L-lysine (1 × 106 cells/100
mm dish) were exposed to 10 Gray (Gy) 137Cs γ-radiation
(Gammacell 3000 Elan, MDS Nordion, Canada) and har-
vested after 48 h.
Subcellular fractionation
An equal ratio (1:1) of treated and untreated MDA-MB-
231 cells were mixed and fractionated using the ProteoJET™
Cytoplasmic and Nuclear Protein Extraction Kit K0311
(Fermentas, Canada) according to the manufacturer’s in-
structions. The efficacy of fractionation was determined via
western blotting using GAPDH and Lamin A/C as the
cytosolic and nuclear control proteins, respectively. BIO-
CON (Suwon, Korea) was conducted to identify proteins al-
tered by irradiation.
Database searching
The tandem mass spectra were extracted, and Sorcerer
3.4 beta2 (Sorcerer software 3.10.4, Sorcerer Web inter-
face 2.2.0.r334) was used to deconvolute and de-isotope
the charge states. All of the MS/MS samples were ana-
lyzed using Sequest (Thermo Fisher Scientific, San Jose,
CA, USA; version 1.3.0.339) set up to search the IPI
HUMAN 3.87 database (unknown version, 91464 en-
tries) assuming trypsin digestion. Sequest was searched
with a fragment ion mass tolerance of 0.8 or 1.0 Da and
a parent ion tolerance of 10.0 PPM. The cysteine iodoa-
cetamide derivative was specified in Sequest as a fixed
modification. Deamidated asparagine and glutamine,
13C-lysine, 13C- and 15N-arginine, oxidized methionine,
acetylated lysine, and phosphorylated serine, threonine,
and tyrosine were specified as variable modifications.
Quantitative data analysis
Scaffold Q+ (version 3.6.2, Proteome Software Inc.,
Portland, OR, USA) was used to validate MS/MS-based
peptide and protein identifications. Peptide identifica-
tions were accepted if they were established at greater
than 95.0% probability by the Peptide Prophet algorithm
[14]. Protein probabilities were assigned by the Protein
Prophet algorithm [15], and identifications were accepted
if they were established at greater than 99.0% probability
and contained at least two unique identified peptides. Ex-
perimentally acquired intensities were globally normalized
across all acquisition runs. Individual quantitative samples
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for identified peptides were normalized within the
assigned protein. The reference channels were normal-
ized to produce a 1:1 fold change. All normalization
calculations were performed using medians to multi-
plicatively normalize data.
Western blot
Cells were lysed with RIPA buffer (50 mM Tris–Cl, pH
7.4, 1% NP-40, 150 mM NaCl, 1 mM EDTA) supple-
mented with protease inhibitors (1 mM phenylmethyl-
sulfonyl fluoride, 1 μg/mL aprotinin, 1 μg/mL leupeptin,
and 1 mM Na3VO4). Proteins from whole cell lysates
were separated on 8–15% SDS-polyacrylamide gels and
transferred to nitrocellulose membranes (Bio-Rad,
Hercules, CA, USA). The membrane was blocked with
5% skim milk in Tris-buffered saline containing 0.1%
Tween-20 (TBS-T) for 1 h and probed with primary
antibodies overnight at 4°C. Primary antibodies for ca-
thepsin D (CTSD), gelsolin (GSN), argininosuccinate
synthase 1 (ASS1), and C-type mannose receptor 2
(MRC2) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA), and the primary antibody for
GAPDH was obtained from AbFrontier (Seoul, Korea).
After multiple washes, membranes were incubated
with peroxidase-conjugated secondary antibodies, and
immunoreactive bands were detected using enhanced
chemiluminescence reagents according to the manu-
facturer’s recommendations (GE Healthcare, Little
Chalfont, UK). Experiments were repeated at least three
times.
Results
Radiation- induced dose-dependent cytotoxicity in
MDA-MB-231 cells
Whereas apoptosis does not activate the immune re-
sponse, necrotic cell death contributes to inflammation
and pathophysiological function through release or se-
cretion of diverse molecules [16]. Therefore, to identify
the immune-related molecules produced by tumor cells
in response to RT, we first investigated the appropriate
radiation dose and harvesting time of MDA-MB-231
cells, highly aggressive and triple-negative breast cancer
cells, by trypan blue exclusion (Figure 1A), MTT
(Figure 1B), and PI staining (Figure 1C) assays. Exposure
to ionizing radiation significantly decreased cell viability in
a dose- and time-dependent manner. Cells exposed to ra-
diation above 10 Gy continued to proliferate after 72 h in
the MTT assay but not in the trypan blue exclusion assay,
indicating that the methods possess different sensitivities
to radiation-induced cell death. In accordance with the
trypan blue assay, the percent cell death determined by
PI staining increased after irradiation. Cells were har-
vested 48 h after 10 Gy of radiation, chosen to evokeradiation-mediated protein alterations but prevent ex-
tensive death, for further experiments. Along with the
radiation dose, the effects of fractionated irradiated
protocols on normal tissue damage and tumor-host in-
teractions are also important in cancer treatment. Cell
survival following single or fractionated irradiation
seems to be similar in in vitro studies when the total
doses are equal [17]. We also measured cell cytotoxicity
after fractionated irradiation up to 10 Gy in 5 daily frac-
tions by trypan blue exclusion (Figure 1D) for comparison
with single-dose irradiation. We observed no differences
in cell cytotoxicity between single- and fractionated-dose
irradiation samples (Additional file 1: Figure S1).
Quantitative proteomic analysis of radiation-induced
proteins in MDA-MB-231 cells
Recently, several studies showed that cells exposed to
fractionated radiation exhibit different signatures com-
pared to those treated with a single dose of radiation
[18-20]. Therefore, to quantitatively analyze proteome al-
terations in tumor cells treated with different fractionation
regimes of radiation, SILAC-based proteomic analysis was
performed. A schematic diagram of the experimental
workflow is provided in Figure 2A. MDA-MB-231 cells in
light media were treated with 10 Gy in a single dose (10
Gy × 1) or in multiple fractionated doses (2 Gy × 5) of ra-
diation. Forty-eight hours after exposure, cytosolic pro-
teins were isolated for analysis (Figure 2B). In duplicated
experiments with single dose radiation, 890 and 977 pro-
teins were identified, respectively, with 734 identified in
both experiments and 525 quantified. In addition, 847 and
792 proteins were identified after multiple fractionated
doses of radiation with 607 identified in both trials and
430 quantified. In total, 314 proteins from MDA-MB-231
cells were simultaneously quantified in both dosing strat-
egies (Figure 2C–E).
Classification of radiation-induced upregulated proteins
A change of 1.3–2.0-fold is generally used as a cut-off
value for significance in SILAC proteomic approaches
[13,21]. Among the 314 proteins quantified, 46 increased
at least 1.3-fold after radiation treatment (Additional
file 2: Table S1). For clear comparison of the results,
we classified the proteins upregulated at least 1.5-fold
as common to both single and fractionated irradiation,
single irradiation-specific-, or fractionated irradiation-
specific (Table 1). Ionizing radiation induced the great-
est increase in fibronectin 1 (FN1), CTSD, GSN, ASS1,
and peroxiredoxin 5 (PRDX5) expression, but the in-
crease in FN1 expression was not statistically significant
(P = 0.1451).
Although most identified proteins were similarly in-
creased in both single- and fractionated-dose radi-
ation, some proteins such as FN1; chondroitin sulfate
Figure 1 Evaluation of cytotoxicity by radiation. MDA-MB-231 cells were treated with the indicated dose of radiation and incubated for 24,
48, or 72 h. Cell viability was determined by trypan blue exclusion assay (A), MTT assay (B), and FACS analysis using propidium iodide (PI)
fluorescent dye (C). (D) MDA-MB-231 cells were treated with a single dose of radiation (10 Gy) or fractionated dose of radiation (2 Gy per day for
5 days). Viable cells were determined by trypan blue exclusion assay 24, 48, or 72 h after final irradiation.
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expressed, developmentally down-regulated 4 (NEDD4);
and low-density lipoprotein receptor-related protein 1
(LRP1) were particularly increased by fractionated ra-
diation. In contrast, single-dose radiation increased the
expression of proteins, including GSN, AHNAK nucleo-
protein, and aldehyde dehydrogenase 2 family, mitochon-
drial (ALDH2) to a greater extent than fractionated-dose
radiation. Additionally, 53 proteins were decreased at
least 1.3-fold by radiation, most of which were identi-
fied as ribosomal proteins (Additional file 2: Table S2).
Gene ontology (GO) analysis was performed on upreg-
ulated proteins using Panther (version 9.0; http://www.
pantherdb.org) according to the GO terms for molecular
function and biological process [22] (Figure 3A and B).
The upregulated proteins were significantly enriched in
molecular functions of catalytic activity (33.3%), binding
activity (29.4%), and structural and molecular activity(19.6%). With regard to biological processes, upregulated
proteins were involved in metabolic processes (21.1%),
cellular processes (21.1%), localization (15.8%), cellular
component organization or biogenesis (11.6%), and de-
velopmental processes (11.6%).
Interaction analysis of selected proteins
Among the top-ranked proteins in SILAC results, five
interesting proteins were selected (FN1, CTSD, GSN,
ASS1, and MRC2) based on P values and immunological
activity potentials. STRING (version 9.1, http://string-db.
org) was used to investigate the interaction potential of
these proteins [13]. Interaction analysis identified close
association of four proteins (FN1, CTSD, GSN, and
ASS1; Figure 3C) and indicated potential interactions
with cluster of differentiation 44 (CD44), integrin alpha
4 (ITGA4), and integrin alpha 5 (ITGA5), which are in-
volved in cell-cell adhesion and immune response.
Figure 2 Venn diagram summary of identified proteins by SILAC-based quantitative proteomics. (A) Schematic workflow for profiling
radiation-induced proteins via proteomic-based analysis. (B) The cytoplasmic lysates from SILAC-labeled cells were analyzed by western blotting
to exclude contamination of nuclear extracts using GAPDH and Lamin A/C as cytosolic and nuclear control proteins, respectively. (C) 734 proteins
were identified in the set of single dose experiments, and (D) 607 proteins were identified in the set of fractionated dose experiments.
(E) Comparison of identified proteins from single or fractionated dose of irradiation.
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four, the interaction network of MRC2 was separately
verified (Figure 3D), identifying interactions with the
plasminogen activator system and anti-inflammatory
proteins such as transforming growth factor-beta (TGF-β)
and interleukin-10 (IL-10).
Identification of potential proteins selected by
quantitative proteomic analysis
Many previous reports have shown that treatment with
ionizing radiation leads to an increase in FN1 expression
and poor prognosis [23-25]. Thus, the expression of other
candidate proteins after irradiation was investigated toconfirm the results of the SILAC proteome approach. The
expressions of CTSD and GSN were significantly induced
by single-dose radiation in a dose-dependent manner, and
the expressions of ASS1 and MRC2 were slightly in-
creased (Figure 4A). Additionally, these four candidates
were also significantly upregulated by the fractionated
dose of ionizing radiation (Figure 4B). The expression
level of candidate proteins induced by a single dose or
multiple fractionated doses of irradiation was normalized
to GAPDH expression. CTSD is synthesized as an inactive
pre-proenzyme that is subsequently converted into an ac-
tive, intermediate proenzyme (46 kDa) and matures after
further cleavage into its more stable two-chain form
Table 1 Up-regulated proteins were identified by a SILAC-based proteomic approach
no Accession No Gene symbol Identified proteins Fold P value* S 1 S 2 F 1 F 2
Commonly up-regulated proteins
1 IPI00022418 FN1 Isoform 1 of Fibronectin 6.525 0.0000 1.7 1.9 17.7 4.8
2 IPI00011229 CTSD Cathepsin D 3.200 0.0000 2.9 3.2 3.4 3.3
3 IPI00026314 GSN Isoform 1 of Gelsolin 2.375 0.0000 3 2.6 2 1.9
4 IPI00020632 ASS1 Argininosuccinate synthase 2.175 0.0007 2.3 2.1 2.4 1.9
5 IPI00024915 PRDX5 Isoform Mitochondrial of Peroxiredoxin-5, mitochondrial 2.025 0.0606 2.9 1.8 1.5 1.9
6 IPI00019157 CSPG4 Chondroitin sulfate proteoglycan 4 1.900 0.3173 1.4 1 2 3.2
7 IPI00218474 ENO3 Isoform 1 of Beta-enolase 1.900 0.0145 1 1 4.6 1
8 IPI00005707 MRC2 C-type mannose receptor 2 1.850 0.0074 1.3 1.2 2.5 2.4
9 IPI00940829 NEDD4 Isoform 4 of E3 ubiquitin-protein ligase NEDD4 1.850 0.0004 1.3 1.3 2.4 2.4
10 IPI00021048 MYOF Isoform 1 of Myoferlin 1.800 0.0000 1.8 1.7 2.4 1.3
11 IPI00021812 AHNAK Neuroblast differentiation-associated protein AHNAK 1.800 0.0047 1.8 2.2 1.6 1.6
12 IPI00020557 LRP1 Prolow-density lipoprotein receptor-related protein 1 1.800 0.0000 1.4 1.4 1.8 2.6
13 IPI00021766 RTN4 Isoform 1 of Reticulon-4 1.725 0.0019 1.6 1.5 1.7 2.1
14 IPI00006663 ALDH2 Aldehyde dehydrogenase, mitochondrial 1.625 0.0262 2.1 1.8 1.4 1.2
Single (10 Gy)
1 IPI00011229 CTSD Cathepsin D 3.05 2.9 3.2
2 IPI00026314 GSN Isoform 1 of Gelsolin 2.8 3 2.6
3 IPI00024915 PRDX5 Isoform Mitochondrial of Peroxiredoxin-5, mitochondrial 2.35 2.9 1.8
4 IPI00020632 ASS1 Argininosuccinate synthase 2.2 2.3 2.1
5 IPI00021812 AHNAK Neuroblast differentiation-associated protein AHNAK 2 1.8 2.2
6 IPI00006663 ALDH2 Aldehyde dehydrogenase, mitochondrial 1.95 2.1 1.8
7 IPI00022418 FN1 Isoform 1 of Fibronectin 1.8 1.7 1.9
8 IPI00021048 MYOF Isoform 1 of Myoferlin 1.75 1.8 1.7
9 IPI00021766 RTN4 Isoform 1 of Reticulon-4 1.55 1.6 1.5
10 IPI00216694 PLS3 Plastin-3 1.55 1.6 1.5
11 IPI00382844 ACO2 Aconitase (Fragment) 1.55 1.5 1.6
12 IPI00013860 HIBADH 3-hydroxyisobutyrate dehydrogenase, mitochondrial 1.55 1.5 1.6
13 IPI00018350 MCM5 DNA replication licensing factor MCM5 1.55 1.6 1.5
14 IPI00098902 OGDH 2-oxoglutarate dehydrogenase, mitochondrial 1.5 1.5 1.5
15 IPI00784156 AP2B1 Isoform 1 of AP-2 complex subunit beta 1.5 1.5 1.5
16 IPI00456969 DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 1.5 1.5 1.5
Fraction (2 Gy × 5)
1 IPI00022418 FN1 Isoform 1 of Fibronectin 11.25 17.7 4.8
2 IPI00011229 CTSD Cathepsin D 3.35 3.4 3.3
3 IPI00218474 ENO3 Isoform 1 of Beta-enolase 2.8 4.6 1
4 IPI00019157 CSPG4 Chondroitin sulfate proteoglycan 4 2.6 2 3.2
5 IPI00005707 MRC2 C-type mannose receptor 2 2.45 2.5 2.4
6 IPI00940829 NEDD4 Isoform 4 of E3 ubiquitin-protein ligase NEDD4 2.4 2.4 2.4
7 IPI00020557 LRP1 Prolow-density lipoprotein receptor-related protein 1 2.2 1.8 2.6
8 IPI00216457 HIST2H2AA3 Histone H2A type 2-A 2.2 2.3 2.1
9 IPI00020632 ASS1 Argininosuccinate synthase 2.15 2.4 1.9
10 IPI00026314 GSN Isoform 1 of Gelsolin 1.95 2 1.9
11 IPI00018398 PSMC3 26S protease regulatory subunit 6A 1.95 2.8 1.1
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Table 1 Up-regulated proteins were identified by a SILAC-based proteomic approach (Continued)
12 IPI00021766 RTN4 Isoform 1 of Reticulon-4 1.9 1.7 2.1
13 IPI00021048 MYOF Isoform 1 of Myoferlin 1.85 2.4 1.3
14 IPI00293464 DDB1 DNA damage-binding protein 1 1.75 1.4 2.1
15 IPI00815770 SNX3 Isoform 1 of Sorting nexin-3 1.75 2.3 1.2
16 IPI00024915 PRDX5 Isoform Mitochondrial of Peroxiredoxin-5, mitochondrial 1.7 1.5 1.9
17 IPI00007682 ATP6V1A V-type proton ATPase catalytic subunit A 1.7 1.7 1.7
18 IPI00021812 AHNAK Neuroblast differentiation-associated protein AHNAK 1.6 1.6 1.6
19 IPI00010418 MYO1C Isoform 2 of Myosin-Ic 1.6 1.8 1.4
20 IPI00000005 NRAS GTPase NRas 1.6 1.6 1.6
21 IPI00006482 ATP1A1 Isoform Long of Sodium/potassium-transporting ATPase subunit alpha-1 1.6 1.4 1.8
22 IPI00023006 ACTC1 Actin, alpha cardiac muscle 1 1.6 2.1 1.1
23 IPI00221035 BTF3 Isoform 1 of Transcription factor BTF3 1.6 1.6 1.6
24 IPI00007402 IPO7 Importin-7 1.55 2.2 0.9
25 IPI00246058 PDCD6IP Programmed cell death 6-interacting protein 1.55 1.7 1.4
26 IPI00026689 CDK1 Putative uncharacterized protein DKFZp686L20222 1.5 1.5 1.5
27 IPI00001960 CLIC4 Chloride intracellular channel protein 4 1.5 1.4 1.6
Proteins increased by an average of 1.5-fold or more are listed.
*Statistical comparisons were performed using the paired z-test, and experimentally verified proteins are represented in bold. S: single-dose irradiation,
F; fractionated-dose irradiation.
Figure 3 Functional analysis for proteins upregulated after irradiation. Gene ontology (GO) classification was performed according to
molecular functions (A) and biological processes (B) using PANTHER (http://www.pantherdb.org/). Interaction network analysis of interesting
proteins including FN1, CTSD, GSN, ASS1 (C), and MRC2 (D) was performed using STRING (http://string-db.org).
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Figure 4 Immunoblot analysis of candidate proteins. MDA-MB-231 cells were exposed to the indicated single (A) or fractionated dose (B) of
radiation. After 48 h, total protein was isolated and examined by western blot. (C) Band intensities corresponding to the indicated proteins were
quantified by densitometry using ImageJ, normalized to the GAPDH loading control, and expressed as fold-change from each control. Values are
mean ± SD for three independent experiments.
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each stage of CTSD cleavage are analyzed in Figure 4C.
Discussion
Radiation therapy is one of the most effective approaches
for cancer treatment [1,2]. However, radioresistance and
recurrence are major obstacles for the long-term sur-
vival of patients undergoing radiation therapy [2,8].
Thus, understanding the mechanisms of radiation-
induced radioresistance and recurrence is important for
the improvement of radiation therapy. In this study,
SILAC-based quantitative proteomic analysis was per-
formed to investigate the radiation-induced changes in
protein expression in MDA-MB-231 cells with single or
fractionated doses of radiation. Although several studies
have analyzed protein profiles altered by radiation, thisis the first report demonstrating and comparatively ana-
lyzing induction of altered molecules by single or frac-
tionated irradiation. Previous studies have employed a
single dose of 5–20 Gy radiation, but typical clinical
fractionation schedules involve treatment with 1.5–2 Gy
per day to a final 60–100 Gy exposure. Moreover, the
efficacy of hypofractionated stereotactic body radiother-
apy was recently evaluated and attracted attention as a
promising curative radiotherapy option. Therefore, it is
worthwhile to concurrently determine the proteomic
profiles of cells treated with a single or fractionated
dose of radiation.
Our results indicate the highest increase in FN1 ex-
pression, but the significance of this finding is modest
due to different profiles after single or fractionated
irradiation. Several studies have shown that ionizing
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sistance, cell motility, and fibrosis [26-30]. Since FN1
expression may be greatly affected by fractionated radi-
ation therapy, fractionated irradiation may cause more
resistance than single dose irradiation. In various hu-
man cancers, especially breast cancer, high levels of
CTSD expression were also reported [31]. Generally,
CTSD plays a role in apoptosis, innate immune re-
sponse, and inflammation but also stimulates growth,
invasion, migration, angiogenesis [32,33], and cellular
senescence in cancer cells [34,35]. Thus, the function of
increased CTSD expression in cancer cells requires
further investigation.
The interaction network of radiation-induced proteins
was examined through STRING analysis. Interestingly,
interactions between FN1, CTSD, GSN, and ASS1 were
indicated, and these proteins were linked with ITGA4,
ITGA5, and CD44. ITGA4 and ITGA5 are well-known
fibronectin receptors that are altered in many cancer
types [27,36]. ITGA4 is overexpressed in chronic
lymphocytic leukemia and associated with migration and
retention in lymph node and bone marrow tissues.
ITGA4 also promotes colony formation, drug resistance,
and tumor-initiation in breast sarcomas [37,38]. Similar
to ITGA4, ITGA5 is involved in cell proliferation, sur-
vival, apoptosis, and angiogenesis [21,27]. In addition,
CD44 is responsible for cell adhesion, cell-cell inter-
action, lymphocyte activation, and tumor metastasis
[39,40]. GSN is a multifunctional actin-binding protein
that controls the length of actin filaments through sever-
ing, capping, and nucleating activities. Changes in GSN
level are observed in numerous human tumors and are
closely related to higher migration capacity, develop-
ment, and progression of cancer [41]. Therefore, we
hypothesize that the FN1, CTSD, and GSN interaction is
associated with cell adhesion and metastasis in tumor
cells.
Several reports have suggested that MRC2 plays a role
in extracellular matrix remodeling and metastasis
[42,43]. Through the STRING analysis, we found that
MRC2 is linked with plasminogen activator system,
TGF-β, and IL-10. In tumor tissues, plasminogen activa-
tor system is closely related to angiogenesis, fibrosis, and
metastasis [44-46]. Moreover, TGF- β is also a well-
known factor in immunosuppression, fibrosis, and the
epithelial-mesenchymal transition (EMT) in tumor cells
[47-49]. The function of anti-inflammatory cytokine
IL-10 in tumor cells remains controversial as it has
both tumor-suppressive and oncogenic roles [50,51].
Several studies have demonstrated that migration and
invasion are promoted by irradiation in breast cancer,
pancreatic cancer, glioma, melanoma, rectal carcinoma,
and colon carcinoma cells [52-58]. Our results suggest
that radiation-induced increases of FN1, CTSD, GSN,and MRC2 may play radioresistant and negative roles in
cancer therapy. Tumor cells killed by radiation treatment
may release molecules unexpectedly but concomitantly
produce favorable factors that protect undamaged tumor
cells, thus increasing invasion or metastasis. However, the
direct effect of those molecules on immune cells has not
been investigated, so candidate proteins can possibly act
as danger signals to stimulate the immune response for
eradication of tumor cells after irradiation [16]. Further
study is required to reveal the function of radiation-
mediated protein expression in dendritic cells and provide
good candidates for increasing radiosensitivity.
Conclusion
Our results demonstrate that CTSD, GSN, and MRC2
are significantly increased in irradiated MDA-MB-231
cells and may be promising targets for predicting or
enhancing the results of radiation therapy. Interest in
combining radiotherapy with other immunotherapeu-
tic agents, such as tumor vaccines, adoptive transfer of
immune cells, and treatment with immune checkpoint
blockers, is increasing. This study provides a front line
approach for establishing the best condition for combined
cancer therapeutics.
Additional files
Additional file 1: Figure S1. Evaluation of cytotoxicity by single or
fractionated radiation. MDA-MB-231 cells were treated with single (10 Gy)
or fractionated (2 Gy per day for 5 days) dose of radiation. Cell viability
was determined by the MTT assay (A) or FACS analysis using propidium
iodide (PI) fluorescent dye (B) 24, 48, or 72 h after the last irradiation.
Additional file 2: Table S1. Up-regulated proteins were identified by a
SILAC-based proteomic approach. Table S2. Down-regulated proteins
were identified by a SILAC-based proteomic approach.
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